PAM2L Biotechnologies announced the completion of over 100 million yuan in Pre-A round financing for the upgrading of their research and development platform and expansion of production capacity. The company, established in March 2021, was co-founded by Dr. Zhong Chao and his university classmate Cui Junfeng. They utilize synthetic biology and machine learning technologies to develop bio-based materials and products. The team comprises top-notch academic achievers with expertise in the field of process engineering. They primarily focus on the development of protein and polysaccharide raw materials, which find wide applications in the fields of pharmaceuticals, medical aesthetics, cosmetics, and food.
Dr. Zhong Chao is a renowned scientist in the field of synthetic biology. He returned to China in 2014 after completing his studies at the Massachusetts Institute of Technology (MIT). In 2020, he joined the Advanced Institute of the Chinese Academy of Sciences in Shenzhen and established the Center for Materials Synthetic Biology. With over ten domestic and international patents, Dr. Zhong Chao has been recognized as the chief scientist of the Synthetic Biology Key Development Program by the Ministry of Science and Technology and has received the National Outstanding Youth Fund.
The core team of the company consists of a doctoral team from top research institutions and an industrialization team from well-known domestic and international enterprises. This ensures the seamless integration of scientific capabilities and commercialization. The advisory team includes renowned scientists and clinical experts from institutions such as MIT, UCSB, Cornell University, Ruijin Hospital, Changzheng Hospital, Shanghai Sixth Hospital, and Shanghai Ninth Hospital.
PAM2L Biotechnologies has established an efficient and innovative research and development platform driven by interdisciplinary in-depth research and long-term accumulation. By combining high-throughput synthetic biology technology, AI methodologies, and optimized pathway design experience, they have gradually developed leading capabilities in the development of novel molecules, materials, and bioactive materials. This significantly accelerates the efficiency of research and development in the field of biomedicine, cosmetic ingredients, functional materials, and other synthetic biology-based innovative materials. The company focuses on high-value and high-growth markets, strategically positioning themselves around core product lines such as proteins and polysaccharides. They are particularly dedicated to advancing the development and commercialization of core product lines including adhesive proteins, bacterial cellulose, and viscous polysaccharides. This enables them to offer green and efficient solutions through innovative applications and substitutions in various scenarios, providing customers with high-value propositions.
Disclaimer: Despite our efforts to maintain accuracy, errors are unavoidable due to our limited expertise. Some information may not be up to date, and we welcome your feedback to make necessary corrections. This document is intended solely for the purpose of providing a business-oriented and written introduction to the field of synthetic biology. It does not constitute any investment advice. We appreciate your understanding.